格里亚丁化纳米颗粒可以提高柏柏林的生物可用性和抗氧化活性
Xiaoxiao Li1, Jihong Huang2, Rui Tan3
1College of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; Key Laboratory of Advanced Technologies of Material, Minister of Education, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; State Key Laboratory of Crop Stress Adaptation and Improvement, College of Agriculture, Henan University, Kaifeng 475004, China.
Food chemistry
|April 8, 2025
概括
这项研究创建了新的纳米颗粒,使用gliadin水解剂来改善柏柏林 (BBR) 输送. 这些纳米粒子显著增强了BBR.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 柏柏林 (BBR) 具有多样化的生理活动,但其生物可用性较差.
- 开发有效的输送系统对于利用BBR的治疗潜力至关重要.
研究的目的:
- 开发可溶性纳米输送载体,使用氨酸化物 (GLH) 提高BBR生物可用性.
- 评估GLH-BBR纳米粒子 (GLH-BBRNP) 的体外和体内性能.
主要方法:
- 纳米粒子配方使用GLH和BBR在5:1质量比.
- 评估封装效率,稳定性和释放动力学.
- 对抗氧化能力 (DPPH,ABTS) 和体内生物利用性的评估.
主要成果:
- 在GLH-BBRNP中实现了BBR的74.95%封装效率.
- 显著增强抗氧化活性:DPPH清除率从19.19%增加到40.28%,ABTS从4.26%增加到60.96%.
- 在肠道中表现出可控释放,并改善了体内生物可用性和抗氧化作用.
结论:
- 基于GLH的纳米颗粒为提高BBR生物可用性和疗效提供了一个有希望的策略.
- 可持续的副产品可以用于先进的药物输送平台.
- 这种方法支持开发高质量的输送系统,用于难以溶解的化合物.
相关概念视频
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
158
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
158
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126


